CRISPR-Cas9 nucleases enable highly efficient genome editing in a wide variety of organisms [1] [2] [3] , but can also cause unwanted mutations at off-target sites that resemble the on-target sequence [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . These offtarget effects can confound research experiments and also have potential implications for therapeutic uses of the technology. Various strategies have been described to reduce genome-wide off-target mutations of the commonly used SpCas9 nuclease, including: truncated sgRNAs bearing shortened regions of target site complementarity 8, 14 , SpCas9 mutants such as the recently described D1135E variant 15 , paired SpCas9 nickases 16, 17 , and dimeric fusions of catalytically inactive SpCas9 to a non-specific FokI nuclease [18] [19] [20] . However, these approaches are only partially effective, have as-yet unproven efficacies on a genome-wide scale, and/or possess the potential to create more new off-target sites. Furthermore, some require expression of multiple sgRNAs and/or fusion of additional functional domains to Cas9, which can reduce targeting range and create challenges for delivery with viral vectors that have limits on nucleic acid payload size. Thus, a major challenge for the field remains the development of a robust and easily used strategy that eliminates off-target mutations on a genome-wide scale.
We initially hypothesized that off-target effects of SpCas9 might be minimized by decreasing non-specific interactions with its target DNA site. SpCas9-sgRNA complexes cleave target sites composed of an NGG protospacer adjacent motif (PAM) sequence (recognized by SpCas9) [21] [22] [23] [24] and an adjacent 20 base pair (bp) protospacer sequence (which is complementary to the 5′ end of the sgRNA) 22, [25] [26] [27] . We previously proposed that the SpCas9-sgRNA complex might possess more energy than is needed for optimal recognition of its intended target DNA site, thereby enabling cleavage of mismatched off-target sites 14 . Structural studies have suggested that the SpCas9-sgRNAtarget DNA complex encompasses several SpCas9-mediated DNA contacts, including direct hydrogen bonds made by four SpCas9 residues (N497, R661, Q695, Q926) to the phosphate backbone of the target DNA strand 28, 29 ( Fig. 1a and Extended Data Fig. 1a, b) . We envisioned that disruption of one or more of these contacts might alter the energetics of the SpCas9-sgRNA complex so that it might retain enough for robust on-target activity but have a diminished ability to cleave mismatched off-target sites.
Alteration of SpCas9 DNA contacts
Guided by this excess energy hypothesis, we first constructed 15 different SpCas9 variants bearing all possible single, double, triple, and quadruple combinations of N497A, R661A, Q695A, and Q926A substitutions to test whether contacts made by these residues might be dispensable for on-target activity (Fig. 1b) . For these experiments, we used a previously described human cell-based enhanced GFP (EGFP) disruption assay 30 . Using an EGFP-targeted sgRNA, which we have previously shown can efficiently induce insertion or deletion mutations (indels) in an EGFP reporter gene when paired with wild-type SpCas9 (ref. 4) , we found that all 15 SpCas9 variants possessed activities comparable to that of wild-type SpCas9 (Fig. 1b, grey bars) . Thus, alanine substitution of one or all of these residues did not reduce on-target cleavage efficiency of SpCas9 with this EGFP-targeted sgRNA.
Next, we sought to assess the relative activities of all 15 SpCas9 variants at mismatched target sites. To do this, we repeated the EGFP disruption assay with derivatives of the EGFP-targeted sgRNA used in the previous experiment that contain pairs of substituted bases at positions ranging from 13 to 19 (numbering starting with 1 for the most PAM-proximal base and ending with 20 for the most PAM-distal base; Fig. 1b ). This analysis revealed that one of the triply substituted variants (R661A/Q695A/Q926A) and the quadruple substitution variant (N497A/R661A/Q695A/Q926A) both showed minimal EGFP disruption at or near background levels with all four of the mismatched
SpCas9-HF1 retains high on-target activities
To determine how robustly SpCas9-HF1 functions at a larger number of on-target sites, we performed direct comparisons between this variant and wild-type SpCas9 using additional sgRNAs. In total, we tested 37 different sgRNAs, 24 targeted to EGFP and 13 targeted to endogenous human gene targets. For 20 of the 24 sgRNAs tested using the EGFP disruption assay (Extended Data Fig. 2a ) and 12 of the 13 sgRNAs tested using a T7 endonuclease I mismatch assay (Fig. 1c) , we found SpCas9-HF1 exhibited at least 70% of the on-target activities observed with wild-type SpCas9 at the same sites (Fig. 1d) . Indeed, SpCas9-HF1 showed highly comparable activities (90-140%) to wild-type SpCas9 with the vast majority of sgRNAs (Fig. 1d) . Three of the 37 sgRNAs tested showed essentially no activity with SpCas9-HF1 (EGFP sites 9 and 23, and RUNX1 site 2), and examination of these target sites did not suggest any obvious differences in the characteristics of these sequences compared to those for which we saw high activities (Supplementary  Table 1 ). Overall, SpCas9-HF1 possesses comparable activities (greater than 70% of wild-type SpCas9 activities) for 86% (32/37 ) of the sgRNAs we tested.
Genome-wide specificity of SpCas9-HF1
To test whether SpCas9-HF1 exhibits reduced off-target effects in human cells, we used the genome-wide unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) method 8 to assess eight different sgRNAs targeted to sites in the endogenous human EMX1, FANCF, RUNX1, and ZSCAN2 genes. The sequences targeted by these sgRNAs have variable numbers of predicted mismatched sites in the reference human genome (Extended Data Table 1 ). Assessment of on-target double-stranded oligodeoxynucleotide (dsODN) tag integration (by restriction-fragment length polymorphism (RFLP) assay) and indel formation (by T7 endonuclease I assay) for the eight sgRNAs revealed comparable on-target activities with wild-type SpCas9 and SpCas9-HF1 (Extended Data Fig. 3a and 3b, respectively), demonstrating that these GUIDE-seq experiments were working efficiently and comparably with the two different nucleases.
These GUIDE-seq experiments showed that with wild-type SpCas9, seven of the eight sgRNAs induced cleavage at multiple off-target sites (ranging from 2 to 25 per sgRNA), whereas the eighth sgRNA (FANCF site 4) did not yield any detectable off-target sites (Fig. 2a, b) . The off-target sites identified harboured one to six mismatches distributed throughout various positions in the protospacer and/or PAM sequence ( Fig. 2c and Extended Data Fig. 4a ). However, with SpCas9-HF1, a complete absence of GUIDE-seq detectable off-target events was observed for six of the seven sgRNAs that induced off-target effects with wild-type SpCas9 (Fig. 2a, b) . Among these seven sgRNAs, only a single detectable genome-wide off-target was identified, for FANCF site 2, at a site harbouring one mismatch within the protospacer seed sequence (Fig. 2a) . As with wild-type SpCas9, the eighth sgRNA (FANCF site 4) did not yield any detectable off-target cleavage events when tested with SpCas9-HF1 (Fig. 2a) . Notably, with all eight sgRNAs, SpCas9-HF1 did not create any new nuclease-induced offtarget sites (not already observed with wild-type SpCas9) detectable by GUIDE-seq.
To confirm these GUIDE-seq findings, we used targeted amplicon sequencing to more directly measure the frequencies of indel mutations induced by wild-type SpCas9 and SpCas9-HF1. For these experiments, we transfected human cells only with sgRNA-and Cas9-encoding plasmids (without the GUIDE-seq tag). We used nextgeneration sequencing to examine the on-target sites and 36 of the 40 off-target sites that had been identified for six sgRNAs with wild-type 
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SpCas9 in our GUIDE-seq experiments (four of the 40 sites could not be specifically amplified from genomic DNA). These deep sequencing experiments showed that: (1) wild-type SpCas9 and SpCas9-HF1 induced comparable frequencies of indels at each of the six sgRNA on-target sites, indicating that the nucleases and sgRNAs were functional in all experimental replicates (Fig. 3a, b) ; (2) as expected, wildtype SpCas9 showed statistically significant evidence of indel mutations at 35 of the 36 off-target sites (Fig. 3b) at frequencies that correlated well with GUIDE-seq read counts for these same sites (Fig. 3c) ; and (3) the frequencies of indels induced by SpCas9-HF1 at 34 of the 36 off-target sites were statistically indistinguishable from the background level of indels observed in samples from control transfections (Fig. 3b) . For the two off-target sites that appeared to have statistically significant mutation frequencies with SpCas9-HF1 relative to the negative control, the mean frequencies of indels were 0.049% and 0.037%, levels at which it is difficult to determine whether these are due to sequencing or PCR error or are bona fide nuclease-induced indels. Based on these results, we conclude that SpCas9-HF1 can completely or nearly completely reduce off-target mutations that occur across a range of different frequencies with wild-type SpCas9 to levels generally undetectable by GUIDE-seq and targeted deep sequencing.
We next assessed the capability of SpCas9-HF1 to reduce genomewide off-target effects of sgRNAs designed against atypical homopolymeric or repetitive sequences. Although we and other researchers now try to avoid on-target sites with these characteristics due to their relative lack of orthogonality to the genome, we wished to challenge the genome-wide specificity of SpCas9-HF1 with sites that have very large numbers of known off-target sites in human cells. Therefore, we used previously characterized sgRNAs 4, 8 that target either a cytosine-rich homopolymeric sequence or a sequence containing multiple TG repeats in the human VEGFA gene (VEGFA site 2 and VEGFA site 3, respectively) (Extended Data Table 1 ). In control experiments, we again found that each of these sgRNAs induced comparable levels of GUIDE-seq dsODN tag incorporation (Extended Data Fig. 3c ) and indel mutations (Extended Data Fig. 3d ) with both wild-type SpCas9 and SpCas9-HF1, demonstrating that SpCas9-HF1 is not impaired in on-target activity with either of these sgRNAs. Importantly, these GUIDE-seq experiments revealed that SpCas9-HF1 was highly effective at reducing off-target sites of these sgRNAs, with 123/144 sites for VEGFA site 2 and 31/32 sites for VEGFA site 3 not detected ( Fig. 4a and Extended Data Fig. 5 ). Examination of wild-type SpCas9 off-target sites not detected with SpCas9-HF1 showed that they each possessed a Figure 2 | Genome-wide specificities of wild-type SpCas9 and SpCas9-HF1 with sgRNAs targeted to standard, non-repetitive sites. a, Off-target cleavage sites of wild-type SpCas9 and SpCas9-HF1 with eight sgRNAs targeted to endogenous human genes, as determined by GUIDE-seq. Read counts represent a measure of cleavage frequency at a given site; mismatched positions within the spacer or PAM are highlighted in colour. b, Summary of the total number of genome-wide off-target sites identified by GUIDE-seq for wild-type SpCas9 and SpCas9-HF1 with the sgRNAs used in panel a. c, Off-target sites identified for wild-type SpCas9 and SpCas9-HF1 for the eight sgRNAs, binned according to the total number of mismatches (in the protospacer and PAM) relative to the on-target site.
range of total mismatches distributed at various positions within their protospacer and PAM sequences: 2 to 7 mismatches for the VEGFA site 2 sgRNA and 1 to 4 mismatches for the VEGFA site 3 sgRNA (Fig. 4b and Extended Data Fig. 4b) ; also, nine of these off-targets for VEGFA site 2 may be recognized by an alternate potential base pairing interaction with the sgRNA that might occur with a single bulged base 12 at the sgRNA-DNA interface (Extended Data Figs 5 and 6) . Overall, the sites that were still mutated by SpCas9-HF1 possessed a range of 2 to 6 mismatches for the VEGFA site 2 sgRNA and 2 mismatches in the single site for the VEGFA site 3 sgRNA (Fig. 4b) , with three of the offtarget sites for the VEGFA site 2 sgRNA having an alternative potential single bulge alignment (Extended Data Figs 5 and 6) . Notably, no new nuclease-induced off-target sites were induced by SpCas9-HF1 with either of the two sgRNAs. Collectively, these results demonstrate that SpCas9-HF1 can be highly effective at reducing off-target effects of sgRNAs targeted to simple repeat sequences and can also have substantial impacts on sgRNAs targeted to homopolymeric sequences.
Refining the specificity of SpCas9-HF1
Previously described methods such as truncated sgRNAs 14 and the SpCas9 D1135E variant 15 can partially reduce SpCas9 off-target effects, and we therefore wondered whether these might be combined with SpCas9-HF1 to further improve its genome-wide specificity. Testing of SpCas9-HF1 with matched full-length and truncated sgRNAs targeted to four sites in the human cell-based EGFP disruption assay revealed that shortening sgRNA complementarity length substantially impaired on-target activities (Extended Data Fig. 7a ). By contrast, SpCas9-HF1 with an additional D1135E substitution (a variant we call SpCas9-HF2) retained 70% or more activity of wild-type SpCas9 with six of eight sgRNAs tested using our human cell-based EGFP disruption assay ( Fig. 5a and Extended Data Fig. 2b) . We also constructed SpCas9-HF3 and SpCas9-HF4 variants harbouring additional L169A or Y450A substitutions, respectively, at positions whose side chains are believed to mediate non-specific hydrophobic interactions with the target DNA on its PAM proximal end 28, 31 (Fig. 1a) . The Y450 residue is notable for participating in a base stacking interaction with the sgRNA 31 and undergoing a 120 degree shift upon target binding to create its hydrophobic interaction with the DNA 28, 32 . SpCas9-HF3 and SpCas9-HF4 retained 70% or more of the activities observed with wild-type SpCas9 with the same six out of eight EGFP-targeted sgRNAs (Fig. 5a and Extended Data Fig. 2b) .
We next sought to determine whether SpCas9-HF2, -HF3, or -HF4 could reduce indel frequencies at two off-target sites that remained susceptible to modification by SpCas9-HF1, one with the FANCF site 2 sgRNA and another with the VEGFA site 3 sgRNA. For the FANCF site 2 off-target, which bears a single mismatch in the seed sequence of the protospacer, we found that SpCas9-HF4 (containing the additional Y450A substitution) reduced indel mutation frequencies to near background level as judged by T7 endonuclease I assay, while also beneficially Table 4 ). Hypothesis testing using a one-sided Fisher exact test with pooled read counts found significant differences (P < 0.05 after adjusting for multiple comparisons using the Benjamini-Hochberg method) for comparisons between SpCas9-HF1 and the control condition only at EMX1 site 2 off-target 1 and FANCF site 3 off-target 1. Significant differences were also found between wild-type SpCas9 and SpCas9-HF1 at all off-target sites, and between wild-type SpCas9 and the control condition at all off-target sites except RUNX1 site 1 off-target 2. c, Scatter plot of the correlation between GUIDE-seq read counts (from Fig. 2a ) and mean per cent modification determined by deep sequencing at on-and off-target cleavage sites with wild-type SpCas9. 
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increasing on-target activity (Fig. 5b) , resulting in the greatest increase in specificity among the three variants (Fig. 5c) . For the VEGFA site 3 off-target site, which bears two protospacer mismatches (one in the seed sequence and one at the nucleotide most distal from the PAM sequence), SpCas9-HF2 (containing the additional D1135E substitution) showed near background levels of indel formation as determined by T7 endonuclease I assay while showing modest effects on on-target mutation efficiency (Fig. 5b) , leading to the greatest increase in specificity for this off-target site among the three variants tested (Fig. 5c ).
Discussion
The SpCas9-HF1 variant characterized in this report reduces all or nearly all genome-wide off-target effects to undetectable levels as judged by GUIDE-seq and targeted next-generation sequencing, with the most robust and consistent effects observed with sgRNAs designed against standard, non-repetitive target sequences. Our observations suggest that off-target mutations might be minimized by using SpCas9-HF1 to target non-repetitive sequences that do not have closely matched sites (for example, bearing 1 or 2 mismatches) elsewhere in the genome; such sites can be easily identified using existing publicly available software programs 33 . An interesting question will be to determine whether SpCas9-HF1 induces off-target mutations at frequencies below the detection limit of existing unbiased genome-wide methods (Supplementary Discussion). We also discuss other practical considerations for targeting sites of interest with SpCas9-HF1, including the use of sgRNAs with non-G or mismatched 5′ nucleotides (Extended Data Fig. 7b ) and altering the PAM recognition specificity of SpCas9-HF1 (Extended Data Fig. 8 ), in the Supplementary Discussion.
Further biochemical experiments and structural characterization will be required to define the mechanism by which SpCas9-HF1 achieves its high genome-wide specificity. We do not believe that the four substitutions we introduced alter the stability or steady-state expression level of SpCas9 in human cells, because titration experiments with decreasing concentrations of expression plasmids suggest that wild-type SpCas9 and SpCas9-HF1 behave comparably as their amounts are lowered (Extended Data Fig. 9 ). Although our initial rationale for making the substitutions in SpCas9-HF1 was to decrease the energetics of interaction between the Cas9-sgRNA complex and the target DNA (as has been previously proposed to explain the increased specificities of transcription activator-like effector nucleases bearing substitutions at positively charged residues 34 ), recent work has provided greater mechanistic insights into SpCas9 recognition and cleavage. These studies suggest alternative and more detailed models (for example, formation of an active cleavage complex through conformational changes or kinetics of off-target site recognition 35, 36 that might be affected by the substitutions in our SpCas9-HF1 variant (Supplementary Discussion)).
More broadly, our results validate a general strategy for the engineering of additional high-fidelity variants of CRISPR-associated nucleases. We found that introducing substitutions at other non-specific DNA contacting residues can further reduce some of the very small number of residual off-target sites that persist for certain sgRNAs with SpCas9-HF1. Thus, we envision that variants such as SpCas9-HF2, SpCas9-HF4, and others might be used in a customized fashion to eliminate any potential off-target sites that might be resistant to the specificity improvements of SpCas9-HF1. In addition, our variants might be combined with substitutions in residues that contact the nontarget DNA strand, alterations that have been shown to reduce SpCas9 off-target effects while our manuscript was under review 37 . Overall, our results demonstrate that the approach of mutating non-specific DNA contacts is highly effective at increasing SpCas9 specificity and suggest it might be extended to other naturally occurring and engineered Cas9 orthologues [38] [39] [40] [41] [42] , as well as other CRISPR-associated nucleases 43, 44 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 30 were cultured in advanced DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2 mM GlutaMax, and penicillin and streptomycin at 37 °C with 5% CO 2 . The growth media for U2OS. EGFP cells was additionally supplemented with 400 µ g ml − 1 Geneticin. All cell culture reagents were obtained from Life Technologies. Cell line identity was validated by STR profiling (ATCC) and deep-sequencing, and cells were tested bi-weekly for mycoplasma contamination. Unless otherwise noted, cells were co-transfected with 750 ng of Cas9 plasmid and 250 ng of sgRNA plasmid. For negative control experiments, Cas9 plasmids were co-transfected with a U6-null plasmid. Nucleofections were performed using the DN-100 program on a Lonza 4-D Nucleofector with the SE Cell Line Kit according to the manufacturer's protocol (Lonza). For T7 endonuclease I assays, GUIDE-seq experiments, and targeted deep sequencing, genomic DNA was extracted ∼ 72 h post-transfection using the Agencourt DNAdvance Genomic DNA Isolation Kit (Beckman Coulter Genomics). Human cell EGFP disruption assay. EGFP disruption experiments, in which cleavage and induction of indels by non-homologous end-joining (NHEJ)-mediated repair within a single integrated EGFP reporter gene leads to loss of cell fluorescence, were performed as previously described 4, 30 . Briefly, transfected cells were analysed ∼ 52 h post-transfection for loss of EGFP expression using a Fortessa flow cytometer (BD Biosciences). Background EGFP loss was determined using negative control transfections gated at ∼ 2.5% for all experiments (represented as a red dashed line in figures). P values for comparisons between SpCas9 variants were calculated using a one-sided t-test with equal variances and adjusted for multiple comparisons using the method of Benjamini and Hochberg (Supplementary Table 3 ). T7 endonuclease I assays. To quantify mutagenesis frequencies at desired genomic loci, T7 endonuclease I assays were performed as previously described 30 . Briefly, on-or off-target sites were amplified from ∼ 100 ng of genomic DNA using Phusion Hot-Start Flex DNA Polymerase (New England Biolabs) using the primers listed in Supplementary Table 2 . An Agencourt Ampure XP cleanup (Beckman Coulter Genomics) was performed before the denaturation and annealing of ∼ 200 ng of the PCR product, followed by digestion with T7 endonuclease I (New England Biolabs). Purified digestion products were quantified using a QIAxcel capillary electrophoresis instrument (Qiagen) to approximate the mutagenesis frequencies induced by Cas9-sgRNA complexes. P values for comparisons between SpCas9 variants were calculated using a one-sided t-test with equal variances and adjusted for multiple comparisons using the method of Benjamini and Hochberg (Supplementary Table 3) . GUIDE-seq. GUIDE-seq relies on the integration of a short dsODN tag into DNA breaks to enable amplification and sequencing of adjacent genomic sequence, with the number of tag integrations at any given site providing a quantitative measure of cleavage efficiency 8 . GUIDE-seq experiments were performed and analysed essentially as previously described 8 . Briefly, U2OS cells were transfected with 750 ng of Cas9 and 250 ng sgRNA plasmids as described above, along with 100 pmol of a GUIDE-seq end-protected dsODN that contains an NdeI restriction site 8 . Restriction-fragment length polymorphism (RFLP) assays were used to estimate GUIDE-seq tag integration frequencies at the intended on-target sites as pre viously described 15 , using the primers listed in Supplementary Table 2 .
The overall on-target mutagenesis frequencies of GUIDE-seq tag-treated samples was determined by T7 endonuclease I assay as described above. Tag-specific amplification and library preparation 8 were performed before high-throughput sequencing on an Illumina MiSeq instrument. GUIDE-seq data was analysed as previously described 8 using open-source GUIDE-seq analysis software (http://www.jounglab. org/guideseq) and the summarized results can be found in Supplementary Table 4 . Genomic sites were excluded from analysis on the basis of overlap with background genomic breakpoint regions detected in any of four oligo-only control samples, overlap with previously identified Cas9-sgRNA independent breakpoints in human U2OS cells 8 , or as neighbouring genomic window consolidation artefacts likely due to extensive end-resection around breakpoints (Supplementary Table 4 ). Potential RNA-or DNA-bulge sites 12 (Extended Data Fig. 6 ) were identified by sequence alignment with Geneious version 8.1.6 (http://www.geneious. com) 45 . Sequencing data was corrected for U2OS cell-type specific SNPs with the site encoding the smallest edit distance to the intended sgRNA site used as the most likely off-target (Supplementary Table 4 ). Differences in number of GUIDE-seq identified off-target sites between this work and previous studies 8, 15 are likely due to different experimental conditions (for example, different promoters, quantity of plasmids used for transfection) and/or to sampling effects at the limit of detection of these particular experiments (Supplementary Table 4) , and most likely not due to depth of sequencing which was similar between experiments.
Positional profiles generated from GUIDE-seq data (Extended Data Fig. 4 ) were made by weighting each nucleotide at each on/off-target site by the number of GUIDE-seq read counts. Sites containing gapped alignments relative to the human genome were not considered. Positional profiles for potential genomic off-target sites were restricted to sequences containing five or fewer mutations relative to the on-target site and to sequences containing NGG PAMs. Heat maps were generated with R 3.2.2 and the image function, with colours determined using the function colorRampPalette(c("white", "blue"))(2500). Targeted deep-sequencing. Off-target sites identified by GUIDE-seq were amplified using Phusion High-Fidelity DNA polymerase (New England Biolabs) using the primers listed in Supplementary Table 2 for the genomic amplicons listed in Supplementary Table 5 . PCR products were generated for each on-and off-target site from ∼ 100 ng of genomic DNA extracted from U2OS cells. Products were generated from triplicate transfections for each of three experimental conditions: (1) control (wild-type SpCas9 + pSL695, a control plasmid that contains a U6 promoter but does not encode a functional sgRNA), (2) wild-type SpCas9 + sgRNA, and (3) SpCas9-HF1 + sgRNA. PCR products were purified with Ampure XP magnetic beads (Agencourt), normalized in concentration, and pooled into nine samples (individual triplicate experiments for each of the three conditions listed above). Illumina Tru-seq compatible deep-sequencing libraries were prepared using ∼ 500 ng of each pooled sample using a 'with-bead' HTP library preparation kit (KAPA BioSystems), and sequenced via 150-bp paired-end sequencing on an Illumina MiSeq instrument. High-throughput sequencing data was analysed essentially as previously described 18 . Breifly, paired reads were mapped to the human genome (reference sequence GRChr37) using the bwa mem algorithm with default parameters. High-quality reads (average quality score ≥ 30) were analysed for the presence of two or more bp indels that overlapped to the on-or off-target sites (Supplementary Table 5 ). One bp indel mutations were only included if they occurred directly adjacent to the predicted cleavage site. P values for comparisons between control, wild-type SpCas9 + sgRNA, and SpCas9-HF1 + sgRNA (Supplementary Table 5 ) were obtained on pooled triplicate data using a one-sided Fisher exact test in the R 3.2.2 software package. P values for each set of comparisons were adjusted for multiple comparisons using the method of Benjamini and Hochberg (function p.adjust(method = "BH") in R). Code availability. Scripts for GUIDE-seq analysis (v0.9) can be found at http:// jounglab.org/guideseq. The scripts used for indel calling on deep sequencing data and GUIDE-seq profiles are available upon request. 
